Scancell to List on Nasdaq via Merger with US-based Neuphoria

Key Facts

In a strategic move reflecting the drive of UK biotech firms to access global capital markets, Scancell Holdings has announced an all-share merger with US-based Neuphoria Therapeutics. According to reports, the primary objective of this deal is to secure a Nasdaq listing for Scancell under the ticker SCLT, while maintaining its existing AIM listing in London. This transition is designed to provide the company with direct access to American institutional investors and enhanced market liquidity.

The merger is accompanied by a comprehensive $89 million funding package consisting of equity and debt, primarily intended to fund global Phase III clinical trials for advanced melanoma. Under the pro forma terms, existing Scancell shareholders will retain 85.5% of the combined entity, with Neuphoria holders taking 14.5%. The financing includes a non-binding debt facility of up to $25 million from BlackRock-managed funds and approximately $10 million from Neuphoria’s existing cash reserves.

Operationally, this capital injection is expected to extend the group's cash runway into 2029, supporting clinical progress until a primary readout in late 2028. As of the market snapshot on July 23, 2026, specific price levels for the instruments are unavailable; however, the outlook remains focused on the company's utilization of its US FDA fast-track designation to accelerate the development of its lead immunotherapy treatments.